Last updated: 2026-10-14 14:58:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Omeros Corporation (OMER) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18.94, with a market capitalisation of $1.42B and a P/E ratio of 10.95. Over the past 52 weeks, its price has ranged from $4.06 to $21.24. This page covers its latest market performance, valuation, price trends and company information.
$1.42B | |
$18.58 | |
$30.23 | |
$0.92 | |
$18.88 | |
138.54K | |
1.73M | |
10.95 | |
$21.24 | |
$4.06 | |
-- | |
-- |
Omeros Corporation (OMER) is currently trading at $18.94 as of 2026-10-14 14:57:00, up 0.31% ($0.06) from the previous close of $18.88
During today's regular trading session, OMER has traded between $0.92 and $30.23, with a trading volume of 138.54K shares. The current price is near the middle of today's range.
Over the past seven days, Omeros Corporation (OMER) moved from $18.90 to $18.94, representing a gain of 0.21% ($0.04).
The stock traded between $18.02 and $20.24 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 925.61 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 86.6%
OMER is currently trading at $18.94, placing it 86.6% of the way from its 52-week low of $4.06 to its 52-week high of $21.24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 175 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Omeros Corporation (OMER) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.